What's Happening?
The U.S. Food and Drug Administration (FDA) announced that it will begin using the term 'Super Intelligence' (SI) instead of 'artificial intelligence' (AI) in all new public-facing communications, effective
November 16, 2026. This change is in compliance with Executive Order 14434, titled 'Inaugurating the Era of Super Intelligence,' issued by President Donald Trump on September 29. The executive order mandates that federal agencies replace references to AI with SI in official, non-statutory materials. The FDA clarified that this terminology shift does not alter existing submission requirements, regulations, or product names for regulated entities. The agency will continue to use original AI terminology when quoting statutes or regulations that specifically use those terms. The FDA has also launched an online SI resource hub to provide information on how it is incorporating these advanced computational technologies into its operations and supporting innovation in regulated industries.
Why It's Important?
The FDA's adoption of 'Super Intelligence' terminology, driven by a presidential executive order, signifies a broader governmental effort to reframe the discourse around advanced computational technologies. While the change is primarily administrative and does not immediately alter regulatory requirements for companies, it underscores the increasing focus on these technologies within federal agencies. For industries regulated by the FDA, such as pharmaceuticals, biotechnology, and medical devices, this shift highlights the growing importance of SI applications in product development, safety monitoring, and innovation. The FDA's commitment to supporting the responsible development of these technologies, while ensuring safety and effectiveness, indicates that future regulatory guidance and evaluation processes will increasingly consider SI-based tools. This move could influence how companies strategize their research and development, potentially encouraging greater integration of advanced computational methods.
What's Next?
The FDA will proceed with incorporating the 'Super Intelligence' terminology into newly issued public-facing materials and updating its online resources, forms, and databases through normal maintenance processes. Regulated entities are not required to revise existing product names or submission materials solely due to this terminology change. However, the FDA's expanded focus on advanced computational technologies suggests that future guidance and policies may further detail how SI-enabled tools can be integrated into regulated development programs. Industry stakeholders, particularly in the life sciences sector, will be closely monitoring for any subsequent agency guidance on the application of SI in product research, development, and review, ensuring compliance with evolving standards for product quality, safety, and effectiveness. The agency's SI resource hub will serve as a central point for updates and information.
Beyond the Headlines
The shift from 'artificial intelligence' to 'Super Intelligence' by a key regulatory body like the FDA, mandated by an executive order, carries implications beyond mere semantics. It reflects a deliberate attempt to shape public perception and policy direction regarding these technologies, potentially signaling a more ambitious vision for their capabilities and integration across sectors. This rebranding could influence public trust, investment trends, and the ethical frameworks surrounding advanced AI. While the FDA emphasizes continuity in regulatory requirements, the new terminology might subtly encourage a more expansive view of what these technologies can achieve, potentially accelerating their adoption and the development of more sophisticated applications. This linguistic shift could also set a precedent for other federal agencies, leading to a broader governmental embrace of the 'Super Intelligence' concept and its associated policy implications.








